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To analyze patterns of antihypertensive drug use among new users in a Southern European
population, and identify patient- and treatment-related factors that influence persistence.
Methods
This is a retrospective observational study of new antihypertensive drug users aged�40
years in Aragón, Spain. Information on antihypertensive drugs (2014–2016) prescribed and
dispensed at pharmacies via the public health system were collected from a regional elec-
tronic population-based pharmacy database. Persistence was assessed using the gap
method. Kaplan-Meier and Cox regression analyses were conducted to analyze patterns of
use and factors that influence persistence.
Results
The 25,582 new antihypertensive drug users in Aragón during the study period were pre-
scribed antihypertensive drugs in monotherapy (73.3%), fixed combination (13.9%), free
combination (9.1%), or other (3.7%). One in five received antihypertensive drugs within 15
days of the prescription date, but not after. During the first year of follow-up, 38.6% of the
study population remained persistent. The likelihood of treatment discontinuation was
higher for participants who were male, aged�80 years, and received an antihypertensive
drug in monotherapy compared with fixed combination.
Conclusion
Overall persistence with antihypertensive therapy was poor, and was influenced by the sex,
age and type of therapy. Fixed combinations appear to be a good choice for initial therapy,
especially in patients with a higher risk of discontinuation. Nonetheless, adverse drug effects
and the patient’s preferences and clinical profile should be taken into account.
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Introduction
Antihypertensive drugs have proven to significantly reduce cardiovascular events by lowering
blood pressure [1]. However, health outcomes in patients treated with these drugs do not
always correspond with expectations [2].
The European Ascertaining Barriers to Compliance (ABC) project developed a taxonomy to
standardize both the medication-taking behavior terminology and the evaluation of medication
adherence [3]. According to this taxonomy, adherence is the process by which patients take their
medications as prescribed, and has three different components or phases: initiation, implementa-
tion and discontinuation. Persistence with therapy refers to the last phase, and it is defined as the
time between initiation of therapy and the last dose, which immediately precedes discontinuation.
Poor treatment persistence is the primary cause of loss of effectiveness of preventive cardio-
vascular medication [4, 5], and contributes to increases in healthcare utilization and overall
healthcare costs [6].
The literature describes antihypertensive drug persistence rates ranging from 35% to 92%
after 1 year [7]. However, accurate comparison of published results is hindered by differences
in patient populations, follow-up duration, definitions of persistence, and data sources.
The use of pharmacy records as sources of information for epidemiological drug utilization
studies has recently become widespread [8]. These sources can be used to investigate relation-
ships between patterns of drug use and population and treatment characteristics. In the case of
antihypertensive drugs, assessment of persistence using this kind of data poses some methodo-
logical challenges, mainly owing to the variety of potential drugs, doses, drug combinations,
and indications. Moreover, most of the published studies classify antihypertensive drug users
whose regimens are switched or added to during the follow-up as discontinuers, providing an
unreal estimate of persistence.
The analysis of factors that influence persistence is of particular interest for the manage-
ment of cardiovascular disease, and there is some controversy in the literature regarding the
influence of the sex, age, initial drug class and type of therapy on persistence to antihyperten-
sive drug treatment [9–12].
In this study, we describe patterns of antihypertensive drug use among new users in a Span-
ish population and analyze the influence of patient demographic characteristics and treat-
ment-related factors on persistence.
Material and methods
Study design and data source
This retrospective observational study of antihypertensive drug users was conducted in the
region of Aragón in northeastern Spain. Data were collected from an electronic population-
based pharmacy database; the Information System for Medication Consumption in Aragon. It
collects the following information for all prescriptions dispensed in pharmacies in Aragon via
the public National Health Service: anonymous patient code, patient sex and birth date, dis-
pensing date, Anatomic Therapeutic Chemical (ATC) code of the prescribed drug, number of
Defined Daily Doses (DDD), and number of packages dispensed.
This source is complete, contains validated data, and has been used in previous drug utiliza-
tion studies [13].
Drugs were identified according to the ATC/DDD classification [14], World Health Orga-
nization 2018. We included all therapeutic subgroups indicated for arterial hypertension treat-
ment (ATC codes C02 [antihypertensives], C03 [diuretics], C07 [beta-blocking agents], C08
[calcium channel blockers], and C09 [agents acting on the renin-angiotensin system]).
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Study population
The study population consisted of all individuals aged�40 years in the region of Aragón who
began antihypertensive treatment for the first time (new users) during 2015. Individuals <40
years were not considered because of the low frequency of hypertension at this age.
The population in Aragón on January 1st 2015 was about 1.3 million, of which about
752,000 people were aged�40 years and 99% were covered by the public healthcare system.
Outcome variables
New users were defined as those that had not been prescribed any antihypertensive drug dur-
ing the 365 days preceding the index date (i.e., the date of the first prescription). For each sub-
ject, age on the index date was calculated.
New users were stratified into four cohorts based on the type of therapy received during a
15-day period after the index date (index period). The consideration of the index period was
because antihypertensive therapy prescribing is initiated in a gradual manner in certain
patients, depending on their needs and response. Taking into account all drugs prescribed dur-
ing this first period may therefore reduce the risk of misclassification of antihypertensive drug
users:
a. Monotherapy: individuals treated with a single active principle during the index period.
b. Fixed combination: individuals treated with multiple active principles combined in a single
formulation during the index period.
c. Free combination: individuals treated with a combination of single active principles in dif-
ferent formulations during the index period.
d. Multiple mix: individuals that received a treatment other than the aforementioned thera-
pies (e.g. monotherapy and a fixed combination) during the index period.
Persistence was defined as the continuation of treatment from the index date to the date of
discontinuation, and was evaluated using the gap method. Antihypertensive drug users were
considered non-persistent or discontinuers if, during the follow-up period, the database
revealed a gap more than twice the duration of the preceding prescription during which no
medication was dispensed. This gap length was based on previous studies [15, 16]. The number
of days of available medication was estimated based on the number of DDD in the most
recently dispensed prescription. Therefore, the maximum gap allowed was estimated as twice
the number of DDD. Subjects were censored if no new prescription was dispensed during
course of the permitted gap, or upon reaching the end of the study period. Thus, the year 2014
corresponded to the “wash-out” period, 2015 to the study “recruitment” period, and 2016 to
the “follow-up” period.
Antihypertensive drug users were classified according to their pattern of use as persistent;
discontinuers; discontinuers who restarted during the study period; or spot users. Spot users
were those that filled prescriptions exclusively during the index period, i.e. within 15 days of
the index date. Upon identification, spot users were excluded from subsequent analyses.
In both the monotherapy and fixed combination cohorts, the initially prescribed therapy
could have been changed during the follow-up period. Switching was defined as a switch from
a single active principle to a different active principle or from a fixed combination to a differ-
ent fixed combination or a free combination. Add-on was defined as the addition of a separate
drug to the single active principle or the fixed combination initially prescribed. A change from
a single active principle to a fixed combination in which one of the constituent drugs belonged
to the same therapeutic subgroup was also considered add-on.
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On the other hand, the type of cohort influenced the type of persistence assessed, i.e., class
persistence (persistence with a medication from the same antihypertensive drug class) or ther-
apy persistence (persistence with any antihypertensive medication). In line with previously
published methodologies [8, 10], we measured class persistence in the monotherapy and fixed
combination cohorts, and therapy persistence in the free combination cohort.
New users of ATC code C02 drugs and those assigned to the multiple mix cohort were not
included in the persistence nor in subsequent analyses because of their low frequency and
heterogeneity.
Statistical analysis
The sex and age profile of the study population and the most prescribed drugs in each of the
study cohorts were described. Persistence was analyzed using the Kaplan-Meier method, and
differences between user groups using the log-rank test. Median time to discontinuation was
estimated and Cox regression analyses were performed to identify factors influencing the
probability of discontinuation, considering the following independent variables: sex, age
group and type of therapy.
A sensitivity analysis was performed to account for the possible influence of the selected
gap length and the number of DDD as a measure of the daily dose on participant classification.
The proportion of persistent users and the median time to discontinuation were recalculated
for each cohort by applying fixed gap lengths of 30, 60 and 90 days, based on previous research
[9, 16, 17].
All analyses were performed using Stata version 12.1 (StataCorp, College Station, TX,
USA).
Ethical information
The research protocol of the study was approved by the Aragon Health Sciences Institute
(IACS) and the Aragon Health Service, who provided us the corresponding pharmacy claims
data. All data used were anonymized and the results aggregated, making patient identification
impossible. Neither consent to participate nor additional ethics approval were therefore
needed.
Results
Characteristics of new antihypertensive drug users and prescribed
treatments
In total, 25,582 new antihypertensive drug users aged�40 were identified. The majority were
assigned to the monotherapy cohort (73.3%), followed by the fixed combination (13.9%), the
free combination (9.1%) and the multiple mix (3.7%) cohorts (Table 1). The proportion of sub-
jects receiving each type of therapy differed according to sex and age (p<0.001). The frequency
of prescription of antihypertensive drugs in free combinations as initial treatment increased
with age, from 7.3% in the 40–59 years’ age group to 13.5% in those aged�80 years.
The regimens most commonly prescribed in monotherapy or in fixed combination during
the index period are shown in Fig 1. The most widely used regimen was angiotensin-convert-
ing-enzyme inhibitors in monotherapy (31.3%), followed by diuretics (21.9%), angiotensin
receptor blockers (13.2%), and beta blockers (12.8%). On the contrary, the most used drugs in
the free combination cohort (Fig 2) were diuretics (representing 32.7% of the total number of
drugs prescribed to this cohort during the index period), followed by angiotensin-converting-
enzyme inhibitors (23.0%) and beta blockers (20.0%).
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Table 1. Distribution of new antihypertensive drug users aged�40 years in Aragón (Spain) by sex, age group, and type of therapy during the first 15 days of
treatment.
Sex Age group
Women n (%) Men n (%) 40–59 years n (%) 60–79 years n (%) �80 years n (%) Total n (%)
Monotherapy 8,840 (72.0%) 9,907 (74.5%) 7,659 (75.1%) 7,814 (72.4%) 3,274 (71.2%) 18,747 (73.3%)
Fixed combination 1,693 (13.8%) 1,857 (14.0%) 1,435 (14.1%) 1,571 (14.6%) 545 (11.9%) 3,551 (13.9%)
Free combination 1,247 (10.2%) 1,097 (8.3%) 747 (7.3%) 978 (9.1%) 619 (13.5%) 2,344 (9.1%)
Multiple mix 496 (4.0%) 444 (3.3%) 353 (3.5%) 427 (4.0%) 160 (3.5%) 940 (3.7%)
Total 12,276 (100.0%) 13,305 (100.0%) 10,194 (100.0%) 10,790 (100.0%) 4,598 (100.0%) 25,582 (100.0%)
Abbreviations: n, number; %, percentage.
https://doi.org/10.1371/journal.pone.0245610.t001
Fig 1. Frequencies of the antihypertensive regimens most commonly prescribed as monotherapy or fixed combination to new users in Aragón (Spain). The values
indicated represent the percentage of new antihypertensive drug users treated with each antihypertensive regimen either as monotherapy or fixed combination during
the first 15 days of therapy relative to the total number of new users.
https://doi.org/10.1371/journal.pone.0245610.g001
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Pattern of use according to sex, age group and initial type of therapy
Comparison of persistence rates by sex (Fig 3) and by age group (Fig 4) revealed significant dif-
ferences (log-rank, p<0.001). Women were persistent for longest compared with men, while
those aged�80 discontinued therapy much earlier than the other two age groups. In particu-
lar, 25.8% of users aged�80 remained persistent for 1 year from the index date, followed by
users aged 60–79 (40.6%) and users aged 40–59 (42.1%) (Table 2).
The proportion of persistent users also varied depending on the type of therapy prescribed
(Table 2). Overall, 5,771 users (38.6%) starting antihypertensive therapy as monotherapy were
classified as persistent. In the fixed combination cohort, there were 1,263 (43.3%) persistent
users. The free combination cohort had the lowest proportion of persistent users (32.3%), as
well as the greatest proportion of discontinuers who subsequently restarted treatment (50.6%).
Analyses by age group and type of therapy confirmed that users aged�80 showed a lower pro-
portion of persistent users independently of the type of therapy (p<0.001). There were not sig-
nificant differences in the proportion of persistent users by type of therapy among the 40–59
Fig 2. Frequencies of the therapeutic subgroups most commonly prescribed as free combination to new users in Aragón (Spain). The values indicated represent the
percentage of prescriptions of each therapeutic subgroup relative to the total number of prescriptions prescribed as free combination to new antihypertensive drug users
during the first 15 days of therapy.
https://doi.org/10.1371/journal.pone.0245610.g002
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and the 60–79 age groups, except among the free combination users (39.2% versus 32.8%,
p = 0.006).
Of the total new antihypertensive drug users analyzed, 5,005 (19.6%) were spot users. By
type of therapy, distribution of spot users was as follows: 20.0% in the monotherapy cohort,
17.7% in the fixed combination cohort and 13.7% in the free combination group.
Among the persistent users in the monotherapy cohort, 765 (13.3%) switched to another
drug during the follow-up period, and 902 (15.6%) were prescribed an add-on medication.
Among the persistent users in the fixed combination cohort, 252 (20.0%) switched medica-
tion and 96 (7.6%) were prescribed an add-on medication.
Differences in the median time to discontinuation were observed depending on the type of
therapy received: monotherapy cohort, 171 days; fixed combination cohort, 248 days; free
combination cohort, 148 days.
Multivariate analysis results
Table 3 shows the results obtained in both the bivariate and the multivariate analyses. Men
were more likely to discontinue antihypertensive therapy than women (HR, 1.20; 95%CI,
1.15–1.24). Compared with the 40–59 years’ group, the likelihood of discontinuing therapy
was significantly higher for the oldest age group (�80 years) (adjusted hazard ratio [HR], 1.45;
95% confidence interval [CI], 1.38–1.53). As regards the type of therapy, individuals prescribed
Fig 3. Antihypertensive drug persistence during the first year of treatment in users from Aragón (Spain) according to their sex.
https://doi.org/10.1371/journal.pone.0245610.g003
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a fixed combination had in both the univariate and the multivariate analyses a lower likelihood
of discontinuation than those receiving monotherapy. Conversely, the association between
prescribing of a free combination and treatment discontinuation did not reach statistical
significance.
In the sensitivity analyses (S1 Table), the proportions of new antihypertensive users consid-
ered treatment persistent were 1,7%, 42.3% and 59.0% applying gaps of 30, 60 and 90 days,
respectively. These results should be compared with the 38.6% of persistent users obtained
when applying a gap of 2xDDD. Median time to discontinuation was of 46 and 228 days with
gaps of 30 and 60 days, respectively. For the gap of 90 days and also for the gap of 60 days in
the case of the free combination cohort, median time could not be calculated since less than
50% of users had discontinued 365 days after initializing treatment. The proportion of persis-
tent users obtained with the gap of 60 days was similar to the obtained with the gap of 2xDDD
for all the types of therapy () except for the free combination cohort, where 51.4% of users
were classified as persistent, instead of 32.3%.
Discussion
The findings presented here help further our understanding as to the factors that influence the
initial prescribing of antihypertensive drugs and their subsequent use.
In our study population, less than half (38.6%) of the new antihypertensive drug users
remained persistent after 1 year of treatment. Evidence suggests that measurement of
Fig 4. Antihypertensive drug persistence during the first year of treatment in users from Aragón (Spain) according to their age group.
https://doi.org/10.1371/journal.pone.0245610.g004
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persistence is a more accurate means of characterizing patient commitment and treatment
continuity than other indicators usually calculated to describe medication adherence [15].
However, comparison of these findings with those reported for other populations is
Table 2. Classification of new antihypertensive drug users aged�40 years in Aragón (Spain) according to the age group, the initially prescribed type of therapy and
the pattern of use over 1 year from the index date.
Type of therapy Discontinuers n (%) Discontinuers who restart n (%) Persistent n (%) Total n (%)
Age group 40–59 years
Monotherapy 1,098 (18.2%) 2,424 (40.1%) 2,527 (41.8%) 6,049 (100.0%)
Fixed combination 246 (19.9%) 428 (33.7%) 564 (45.6%) 1,238 (100.0%)
Free combination 84 (12.4%) 327 (48.4%) 265 (39.2%) 676 (100.0%)
Total 1,428 (17.9%) 3,179 (39.9%) 3,356 (42.1%) 7,963 (100.0%)
Age group 60–79 years
Monotherapy 1,126 (17.6%) 2,644 (41.4%) 2,614 (41.0%) 6,384 (100.0%)
Fixed combination 304 (23.8%) 415 (32.5%) 560 (43.8%) 1,279 (100.0%)
Free combination 137 (17.1%) 403 (50.2%) 263 (32.8%) 803 (100.0%)
Total 1,567 (18.5%) 3,462 (40.9%) 3,437 (40.6%) 8,466 (100.0%)
Age group�80 years
Monotherapy 628 (25.0%) 1,257 (50.0%) 630 (25.0%) 2,515 (100.0%)
Fixed combination 122 (30.3%) 141 (35.1%) 139 (34.6%) 402 (100.0%)
Free combination 121 (23.4%) 279 (54.1%) 116 (22.5%) 516 (100.0%)
Total 871 (25.4%) 1,677 (48.8%) 885 (25.8%) 3,433 (100.0%)
Total population
Monotherapy 2,852 (19.1%) 6,325 (42.3%) 5,771 (38.6%) 14,948 (100.0%)
Fixed combination 672 (23.0%) 984 (33.7%) 1,263 (43.3%) 2,919 (100.0%)
Free combination 342 (17.4%) 1,009 (50.6%) 644 (32.3%) 1,995 (100.0%)
Total 3,866 (19.5%) 8,318 (41.9%) 7,678 (38.6%) 19,862 (100.0%)
Abbreviations: n, number.
https://doi.org/10.1371/journal.pone.0245610.t002
Table 3. Hazard ratios for discontinuation of antihypertensive therapy in new antihypertensive drug users aged
�40 years in Aragón (Spain).
Unadjusted HR (95%CI) Adjusted HR (95%CI)��
Sex
Women 1 1
Men 1.23 (1.19–1.28)� 1.20 (1.15–1.24)�
Age group
40–59 1 1
60–79 1.04 (1.00–1.08) 1.02 (0.98–1.06)
�80 1.51 (1.44–1.59)� 1.45 (1.38–1.53)�
Type of therapy
Monotherapy 1 1
Fixed combination 0.79 (0.75–0.84)� 0.80 (0.76–0.84)�
Free combination 1.01 (0.95–1.08) 0.99 (0.93–1.06)
Abbreviations: HR, hazard ratio; 95%CI, 95% confidence interval.
N = 19,543.
�Statistically significant result.
��Model adjusted for all other variables indicated in the table.
https://doi.org/10.1371/journal.pone.0245610.t003
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complicated by the wide variety of methodologies used to assess persistence [8, 10, 15, 18],
including differences in inclusion criteria, wash-out periods, and gap lengths.
Of the new antihypertensive drug users comprising the study population, one fifth exclu-
sively purchased antihypertensive drugs on the index date or during the subsequent 15 days.
This observation is in line with the findings of previous studies showing that a considerable
number of users filled only one prescription [8]. Patient concerns about the newly prescribed
therapy and its potential adverse effects are the most commonly cited reasons for early
decrease in persistence [19].
The present study reveals divergences as regards the type of therapy prescribed, with new
users receiving monotherapy, fixed combinations, and free combinations accounting for
73.3%, 13.9%, and 9.1% of the study population, respectively. Guidelines published recently by
the European Society of Cardiology and the European Society of Hypertension [20] recom-
mend a combination of two drugs with distinct mechanisms of action in high-risk hyperten-
sive patients, as this is related to a faster and more effective blood pressure reduction [21]. This
fact could probably explain the higher long-term antihypertensive use in patients starting
treatment with a combination of two drugs, compared with initial monotherapy, found in pre-
vious studies [22]. Our findings corroborate the protective association between receiving a
fixed combination and persistence, compared with monotherapy, but it did not apply to free
combinations. Drugs belonging to the agents acting on renin-angiotensin system subgroup
were the most prescribed as both monotherapy and fixed combination, while diuretics and
beta blockers represented an important proportion of prescriptions within free combinations.
Previous studies have consistently described lowest levels of persistence for these latter, and
the highest rates for agents acting on the renin-angiotensin system [15, 17, 19, 23]. Addition-
ally, diuretics and beta blockers are often indicated for disorders different than hypertension
which, in some cases, require shorter treatment lengths. These situations could explain the
lower persistence rates found in the free combination cohort. On the other hand, it seems
probable that the different age and clinical profile of free combination users influence on their
discontinuation. This hypothesis has been corroborated in the present study since the higher
risk of discontinuation in free combination users disappeared after adjusting by sex and age.
From a methodological perspective, it should also be taken into account that, differently from
the other study cohorts, persistence in the free combination cohort was described as continua-
tion with any of the formulations prescribed, and that free combination cohort was the only
one in which the proportion of persistent users varied importantly when a gap of 60 days was
applied.
In our study population, the youngest hypertensive drug users (aged 40–59 years) were
more often initially treated with fixed combinations, while those aged�80 years were more
often prescribed free combinations. Multivariate analysis of the effect of age on persistence
additionally revealed that the risk of treatment discontinuation was 45% greater in the oldest
(�80 years) than the 40–59 years’ group, independently of the type of therapy. While contrast-
ing results have been reported by some authors [8, 10], other studies have described similar
age-related effects. For instance, Choi et al. [23] concluded that persistence was greater in
elderly patients than young/adult patients, but was poorest in the very elderly. The poorer per-
sistence with increasing age and the greater complexity of these patients may be linked to the
presence of other medical conditions that require attention and a great number of comedica-
tions. Moreover, control of hypertension may not be considered a priority in these patients,
especially in those closer to the end of life.
The existing literature is somewhat ambiguous as regards the influence of sex on antihyper-
tensive drug treatment persistence [8, 10, 12, 23]. In this respect, our results showed that
women were less likely than men to discontinue treatment.
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Several aspects of our study strengthen the validity of our findings. First, the use of an
administrative electronic database allowed assessment of patterns of antihypertensive drug uti-
lization in “real life” conditions in a European population. Second, the inclusion in our analy-
sis of incident, but not prevalent antihypertensive drug users, simplified the evaluation of
medication-taking behavior. Finally, in contrast to previous studies [12, 24] our definition of
persistence included individuals who continued antihypertensive therapy but whose regimens
were switched or added to, thereby avoiding underestimation of true persistence.
A key limitation of our study is the lack of clinical, prescriber or patient socioeconomic
information in the data source used, which could have allowed to ascertain the cause of treat-
ment discontinuation in numerous cases, such as the oldest users. Moreover, the availability of
information on other pharmacological treatments would have been useful for assessing the
effect of polypharmacy on persistence, a relationship with inconsistent findings to date [8, 18].
Pharmacy claim databases like the used do not indicate whether the patient has taken the pur-
chased medication. In this sense, the quantification of persistence seeks to overcome this limi-
tation by providing a measurement of treatment continuity [15]. The use of DDD to estimate
the number of days of available medication assumes that all patients are taking the standard
dose of a given drug. This can be problematic in cases of non-standard regimens, more com-
mon in very elderly patients, or in patients to whom the medication is prescribed for condi-
tions other than hypertension.
To conclude, persistence with antihypertensive drug treatment in our study population was
poor overall, and the very elderly users were the less likely to remain persistent. According to
our findings, fixed combinations seem an appropriate choice as initial therapy regarding the
persistence, and its prescribing is in line with current recommendations. Users of free combi-
nations have shown the lowest frequency of persistence, association probably influenced not
only by their different age, but also by their clinical profile and the type of drugs that they
receive, compared with the other users. Further research controlling for a higher number of
potentially influencing factors than the included in the present study is thus required to con-
firm this scenario. In any case, the antihypertensive regimen should always be selected based
on the patient’s circumstances and clinical status, with patients being included in the decision-
making process. Finally, patients who are prescribed therapies and regimens that are more
likely to be discontinued should be identified and targeted for interventions.
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